Darzalex access in Pakistan: the DRAP named-patient pathway
How patients in the Islamic Republic of Pakistan legally obtain Darzalex (daratumumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Darzalex in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in Pakistan access Darzalex (daratumumab) for multiple myeloma in newly diagnosed and relapsed/refractory settings in combination regimens, and light-chain amyloidosis, under the FDA label through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Darzalex reaches patients in Pakistan
Darzalex (daratumumab, anti-CD38 monoclonal antibody, FDA-approved 2015 for multiple myeloma with subsequent label expansions through newly diagnosed combinations and light-chain amyloidosis; Darzalex Faspro subcutaneous form FDA-approved 2020) is partially visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification through the Janssen distribution channel, but specific presentations, dose strengths, and combination-regimen indications are not always available in stocked form. Where the prescribed dose, formulation (IV versus SC Faspro), or combination indication does not match locally stocked product, Pakistani patients access Darzalex through the Special Permission for Import of Therapeutic Goods for Personal Use, administered by DRAP's QA and LT Division Import and Export Section under the Drugs Act 1976. The application is filed at dra.gov.pk/therapeutic-goods/import-export/special-permissions. The Darzalex-specific clinical justification must document: multiple myeloma stage (ISS or R-ISS), prior lines of therapy, intent to combine with bortezomib, lenalidomide, dexamethasone, or other backbone, and infusion-related-reaction pre-medication plan. For Darzalex Faspro (subcutaneous), the dispensing setting can be ambulatory; for IV daratumumab, infusion-chair capacity is required. DRAP processing for named-patient imports is typically several working days. Cold-chain handling (2 to 8 degrees Celsius) is required throughout; the application package documents the cold-chain plan.
Where Darzalex is administered in Pakistan
Darzalex IV requires infusion-capable medical oncology or haematology day-care with pre-medication and slow first-infusion protocols; Darzalex Faspro SC requires ambulatory injection capacity with monitoring.
What Darzalex costs in Pakistan
Medicine price: quote on request. You get a written quote for your case before you commit.
Funding and access barriers for Darzalex in Pakistan
Multiple myeloma is a relatively common haematologic malignancy in Pakistan (incidence estimated approximately 2 to 3 per 100,000 annually). The Sehat Sahulat Programme inpatient cover may extend to selected myeloma inpatient admissions; outpatient daratumumab maintenance is not consistently covered at the federal-card level. Khyber Pakhtunkhwa Sehat Card Plus has the broadest specialty cover and has historically funded selected oncology biologics on a case-by-case basis. Pakistan Bait-ul-Mal at pbm.gov.pk grants oncology cases case-by-case. Major private insurers do not publish a daratumumab formulary line; corporate group policies with high-cost rider may cover an induction course subject to step-therapy documentation (bortezomib-lenalidomide-dexamethasone backbone failure or contraindication). Janssen Pakistan operates a patient-support programme through local distribution channels for locally-registered presentations; this does not extend to imported presentations or unregistered indication combinations. The DRAP cold-chain customs experience for biologics requires the importing entity to document temperature logging from origin to port, but Pakistani customs operates 24-hour clearance for documented therapeutic goods at major ports (Karachi, Lahore, Islamabad airports).
Recent regulatory and access news for Darzalex
FDA approved (July 2024) Darzalex Faspro plus bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma in transplant-eligible adults based on the PERSEUS trial; the expanded label establishes a daratumumab-containing quadruplet as the new FDA-label standard induction for transplant-eligible newly diagnosed myeloma. The PERSEUS data are summarised in the FDA approval letter at accessdata.fda.gov/scripts/cder/daf. FDA also expanded the Darzalex Faspro label (August 2024) to include high-risk smouldering multiple myeloma. No DRAP-specific bulletin on Darzalex over the last 12 months has been observed as of 2026-05-31. The DRAP consolidated Guidance Document for Imports and Exports at dra.gov.pk regulatory updates remains the operative procedural reference.
Where Reserve Meds fits in Darzalex cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Darzalex specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Darzalex case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Next step
If your Pakistani physician has prescribed Darzalex and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.